hypertens
longterm
medic
condit
known
high
blood
pressur
major
risk
factor
vision
loss
stroke
heart
failur
chronic
kidney
diseas
quarter
world
adult
popul
hypertens
therapeut
approach
focus
reninangiotensinaldosteron
system
raa
regul
blood
pressur
electrolyt
balanc
human
raa
renin
stimul
gener
angiotensin
angi
convert
vasoconstrictor
angiotensin
ii
angii
angiotensin
convert
enzym
ace
two
isoform
somat
testicular
ace
transcrib
ace
gene
tissuespecif
manner
somat
form
sace
zinc
depend
dicarboxypeptidas
includ
two
homolog
domain
n
domain
c
domain
sequenc
ident
zinc
motif
hexxh
x
amino
acid
residu
past
decad
report
c
domain
human
sace
main
angi
convert
site
control
blood
pressur
cardiovascular
function
ace
hydrolyz
decapeptid
aspargvaltyrilehisprophehisleu
angi
cleav
dipeptid
cterminu
produc
octapeptid
aspargvaltyrilehisproph
angii
caus
blood
vessel
narrow
stimul
secret
hormon
aldosteron
result
increas
blood
pressur
ace
also
affect
blood
pressur
inactiv
vasodil
bradykinin
kallidin
therefor
ace
long
major
target
treatment
hypertens
cardiovascular
ailment
use
ace
inhibitor
common
synthet
ace
inhibitor
captopril
enalapril
alacepril
lisinopril
market
decad
howev
report
divers
side
effect
includ
hyperkalemia
skin
rash
impair
renal
function
develop
angioedema
therefor
peptid
natur
sourc
consid
altern
ace
inhibitor
attract
research
interest
structur
ace
complex
variou
ligand
includ
synthet
inhibitor
peptid
avail
protein
data
bank
pdb
crystal
structur
ace
determin
high
resolut
give
us
overal
insight
structur
molecular
arrang
activ
site
crystal
structur
time
ensembl
averag
snapshot
complet
understand
protein
rigid
flexibl
dynam
solut
fluctuat
among
mani
conform
substat
addit
structur
knowledg
dynam
enzym
understand
mechan
activ
inhibit
crucial
design
better
drug
molecular
dynam
md
simul
known
power
tool
molecular
model
investig
dynam
protein
appli
variou
system
success
recent
md
simul
ace
variou
ligand
report
drug
discoveri
molecular
model
interact
enzym
potenti
inhibitor
order
explor
ligand
bind
effect
dynam
mechan
activ
inhibit
allatom
md
simul
sace
carri
without
ligand
simul
focu
c
domain
angi
mainli
convert
ligandfre
simul
apo
observ
mouth
open
close
motion
sace
like
pacman
arcad
game
larg
hing
bend
motion
impli
exist
preexist
backbon
conform
figur
show
overal
structur
enzym
secondari
structur
sace
predominantli
alpha
helic
figur
structur
ellipt
shape
dimens
approxim
cleft
around
activ
site
expand
pdb
id
cleft
divid
sace
two
subdomain
activ
site
locat
inner
surfac
two
subdomain
sace
defin
subdomain
includ
nterminu
zinc
ion
residu
subdomain
ii
includ
cterminu
residu
two
kind
inhibitor
bppb
bradykinin
potenti
peptid
b
gluglyleuproproargprolysilepropro
spi
spirulina
deriv
heptapeptid
thrmetgluproglylyspro
competit
mix
noncompetit
respect
use
investig
differ
inhibit
mechan
mix
type
noncompetit
inhibit
mode
spi
determin
plot
model
inhibit
mechan
studi
previou
studi
simul
ligandfre
sace
apo
initi
coordin
remov
bound
angii
saceangii
complex
pdb
id
like
other
structur
complex
also
close
state
defin
distanc
two
lip
figur
shorter
simul
time
went
enzym
spontan
open
mouth
mouth
gradual
reclos
open
state
return
back
semiopen
open
state
defin
open
state
distanc
longer
semiopen
state
distanc
longer
shorter
observ
multipl
convers
open
close
state
ns
simul
figur
believ
first
work
show
spontan
open
close
motion
ace
md
simul
video
yu
et
al
ran
md
simul
ligandfre
ace
ns
report
open
close
motion
order
analyz
mouth
open
close
motion
defin
two
lip
calcul
distanc
center
lip
atom
throughout
product
stage
simul
figur
two
lip
mouth
defin
lip
subdomain
compos
residu
lip
ii
subdomain
ii
compos
residu
angii
bound
sace
quit
stabl
ns
simul
time
larg
backbon
conform
chang
observ
unlik
apo
form
absenc
ligand
enzym
mainli
stay
close
semiopen
state
throughout
entir
simul
figur
order
investig
flexibl
enzym
rootmeansquar
deviat
rmsd
apo
form
angii
bound
form
comput
figur
expect
rmsd
show
strong
correl
distanc
two
lip
due
mouth
open
motion
conform
apo
form
deviat
far
away
initi
structur
close
conform
reach
nearli
rmsd
valu
howev
rmsd
valu
angii
bound
form
fluctuat
less
compar
unbound
form
ligand
bound
form
rel
stabl
rootmeansquar
fluctuat
rmsf
form
calcul
use
product
stage
md
simul
trajectori
figur
analysi
indic
subdomain
flexibl
subdomain
ii
simul
interestingli
overal
flexibl
subdomain
ii
chang
much
regardless
presenc
angii
signific
differ
two
simul
larg
increment
flexibl
subdomain
apo
form
notic
subdomain
closur
movement
protein
regard
common
mechan
rearrang
critic
group
around
substrat
inhibitor
structur
report
open
conform
human
ace
yet
angiotensin
convert
enzymerel
carboxypeptidas
homologu
human
sace
also
identifi
cellular
receptor
sar
coronaviru
novel
coronaviru
catalyt
domain
sace
share
sequenc
ident
crystal
structur
without
inhibitor
report
first
pdb
id
open
conform
observ
absenc
inhibitor
inhibitor
bound
one
show
close
conform
base
two
structur
author
propos
larg
hingebend
motion
import
catalyt
activ
inhibitor
bind
ace
superimpos
close
open
conform
ace
compar
comparison
reveal
tremend
similar
two
system
figur
addit
distanc
two
lip
calcul
base
sequenc
align
sace
two
lip
identifi
lip
compos
residu
subdomain
lip
ii
compos
residu
subdomain
ii
distanc
lip
lip
ii
comput
close
open
state
respect
result
consist
distanc
analysi
sace
figur
order
test
robust
definit
backbon
conform
state
also
calcul
mouth
open
angl
result
show
similar
pattern
distanc
figur
base
calcul
maxim
hingebend
movement
close
valu
measur
structur
bppb
competit
inhibitor
isol
snake
venom
crystal
structur
show
activ
site
sace
occupi
octapeptid
bppb
close
conform
state
complex
pdb
id
set
anoth
system
bppb
bound
sace
carri
ns
md
simul
angii
product
catalyt
function
ace
also
consid
competit
inhibitor
leav
activ
site
anoth
substrat
angi
bind
site
next
reaction
bppb
bound
sace
simul
show
similar
behavior
angii
bound
one
figur
analyz
distanc
two
lip
mouth
show
conform
chang
close
semiopen
state
back
close
state
figur
bppb
bound
ace
flexibl
angii
bound
one
made
mouth
close
tightli
number
hydrogen
bond
ligand
enzym
calcul
simul
time
figur
averag
number
angii
bppb
respect
tabl
indic
open
close
motion
affect
interact
ligand
enzym
addit
competit
inhibit
noncompetit
inhibit
also
common
inhibit
mechan
noncompetit
inhibit
includ
pure
mix
noncompetit
inhibit
surprisingli
us
mechan
mix
type
noncompetit
inhibit
ace
studi
intens
far
previou
studi
heptapeptid
thrmetgluproglylyspro
deriv
marin
microalga
spirulina
identifi
mix
noncompetit
inhibitor
spi
investig
interact
dynam
ace
bound
mix
noncompetit
inhibitor
md
simul
conduct
spi
bound
apo
form
spi
bound
angiisac
complex
form
simul
spi
bound
sace
start
structur
remov
angii
spi
bound
angiisac
complex
result
spi
dock
simul
previou
studi
analysi
distanc
two
lip
spi
bound
sace
show
backbon
conform
fluctuat
close
semiopen
state
abl
see
open
conform
state
figur
word
spontan
conform
chang
limit
close
semiopen
state
stabil
spi
video
peptid
spi
form
hydrogen
bond
sace
averag
product
stage
whole
simul
tabl
simul
spi
bound
angiisac
complex
peptid
bound
ntermin
side
mouth
next
angii
figur
bind
spi
stabil
hydrogen
bond
interact
sace
also
angii
investig
presenc
hydrogen
bond
md
simul
averag
spi
form
pair
hydrogen
bond
sace
angii
respect
togeth
pair
tabl
spi
form
hydrogen
bond
frequent
sace
spisac
residu
order
angii
spiangii
residu
order
figur
tabl
addit
hydrogen
bond
bind
spi
stabil
van
der
waal
interact
sidechain
spi
bound
hydrophob
pocket
form
sace
shown
figur
clariti
distanc
analysi
spi
bound
saceangii
show
similar
behavior
ligand
bound
simul
figur
interestingli
spi
bound
saceangii
complex
stay
close
state
simul
time
understand
sinc
spi
angii
act
inhibitor
number
hydrogen
bond
ligand
enzym
largest
among
complex
tabl
close
state
stabil
interact
angi
sace
also
interact
spi
sace
addit
interact
spi
angii
stabil
complex
close
state
analysi
five
rmsf
indic
stabl
system
spi
bound
saceangii
complex
figur
recogn
bind
spi
saceangii
complex
slightli
twist
subdomain
figur
activ
site
bind
interact
well
known
ace
variou
inhibitor
conform
dynam
role
activ
mechan
studi
intens
drug
design
might
benefit
backbon
conform
observ
md
simul
never
reach
xray
crystallographi
ligand
bound
form
unlik
close
state
open
state
sace
detect
experi
simul
far
surprisingli
decad
sinc
first
propos
studi
report
role
larg
hingebend
motion
activ
sace
contrast
lockandkey
model
mani
protein
take
ligand
conform
chang
put
bind
pathway
sace
might
narrow
accommod
substrat
angi
close
state
figur
thu
enzym
need
chang
backbon
conform
take
substrat
catalyt
function
least
semiopen
state
rearrang
sidechain
may
allow
substrat
enter
activ
site
figur
two
model
enzym
mechan
inducefit
preexist
equilibrium
dynam
repres
conform
chang
dynam
upon
ligand
bind
former
bind
ligand
induc
conform
chang
protein
latter
ligand
bind
certain
preexist
conform
alreadi
present
access
equilibrium
dynam
ligandfre
apo
md
simul
abl
observ
spontan
conform
chang
open
close
state
sace
impli
open
close
backbon
conform
state
alreadi
present
access
regardless
presenc
ligand
addit
sever
time
convers
state
simul
indic
enzym
flexibl
dynam
inde
avail
ace
structur
resolv
close
conform
either
presenc
ligand
mutat
introduc
mutat
ligand
chimera
common
method
enhanc
thermal
stabil
crystal
protein
addit
absenc
open
conform
ligandfre
ace
impli
intrins
flexibl
ace
one
avail
structur
open
conform
resolv
addit
previou
studi
use
normal
mode
analysi
nma
testicular
ace
tace
anoth
isoform
ace
show
intrins
flexibl
open
close
conform
model
ace
author
also
propos
hingebend
mechan
substrat
entri
activ
site
base
result
md
simul
avail
xray
structur
propos
follow
activ
mechan
sace
figur
regardless
presenc
ligand
sace
could
open
semiopen
close
state
term
backbon
conform
absenc
substrat
angi
open
state
might
favor
close
state
figur
enzym
becom
readi
accept
substrat
catalyt
function
equilibrium
howev
chang
presenc
angi
close
state
becom
stabl
open
state
due
bind
substrat
ctermin
dipeptid
hisleu
angi
hydrolyz
angii
product
enzym
activ
might
releas
sace
semiopen
state
figur
figur
releas
angii
sace
equilibrium
conform
state
goe
back
first
stage
notic
semiopen
conform
access
condit
similarli
deriv
mechan
competit
inhibitor
ligand
competit
inhibitor
bound
complex
becom
stabl
close
state
qualit
equilibrium
shift
way
case
substrat
bind
releas
inhibitor
equilibrium
goe
back
first
stage
apo
form
sinc
angii
occupi
activ
site
releas
angii
sace
take
substrat
true
substrat
interestingli
spi
mix
noncompetit
inhibitor
make
use
interact
spi
sace
also
angii
stabil
sace
close
state
result
deadend
complex
hold
product
enzym
angii
activ
site
sinc
spi
share
bind
site
substrat
becom
noncompetit
even
though
spi
noncompetit
bind
next
activ
site
interact
substrat
becom
mix
type
inhibitor
bind
site
variou
drug
drug
candid
studi
intens
along
variou
ligand
bind
site
conform
variou
indic
bind
specif
ligand
induc
specif
conform
bind
site
therefor
overal
larg
backbon
open
close
conform
state
preexist
sidechain
minor
backbon
rearrang
may
induc
upon
ligand
bind
apo
simul
remov
bound
angii
xray
structur
saceangii
complex
start
md
simul
remov
angii
addit
perturb
sace
structur
check
equilibr
apo
system
monitor
thermodynam
paramet
energi
temperatur
volum
pressur
figur
addit
monitor
evolut
secondari
structur
along
simul
time
recogn
overal
secondari
structur
well
conserv
stabl
except
loop
turn
region
figur
even
though
observ
multipl
open
close
motion
one
still
consid
apo
system
still
equilibr
stage
apo
structur
still
equilibr
stage
goe
certain
open
conform
would
xray
structur
open
conform
like
calorimetr
studi
show
drug
bind
entrop
driven
also
support
dynam
ace
conclus
use
allatom
md
simul
convers
open
close
state
sace
observ
absenc
ligand
support
hingebend
motion
essenti
enzym
activ
prefer
state
well
extent
flexibl
strongli
depend
presenc
ligand
transform
semiopen
close
state
bound
form
directli
influenc
interact
residu
bind
site
substrat
inhibitor
interact
constrain
enzym
structur
remain
semiopen
close
state
howev
would
seem
put
bind
pathway
narrow
accommod
substrat
inhibitor
therefor
semiopen
conform
might
state
ligand
bind
md
simul
result
mechanist
model
sace
activ
inhibit
portend
drug
design
hypotens
treatment
also
wide
applic
molecular
biophys
beyond
potenti
bind
site
spi
sace
search
dock
simul
use
flexpepdock
protocol
rosetta
program
crystal
structur
human
sace
complex
angii
pdb
id
use
target
sinc
spi
peptid
noncompetit
inhibitor
angii
kept
dock
simul
avoid
overlap
bind
site
peptid
activ
site
structur
lowest
score
dock
simul
chosen
molecular
dynam
simul
order
relax
structur
tabl
detail
dock
simul
describ
previou
studi
total
five
molecular
dynam
simul
carri
bppb
bound
sace
angii
bound
sace
apo
ligandfre
spi
bound
saceangii
complex
spi
bound
sace
two
crystal
structur
sace
cocrystal
ligand
activ
site
use
build
simul
system
sace
complex
natur
inhibitori
peptid
bppb
pdb
id
sace
complex
angii
pdb
id
order
simul
apo
form
angii
remov
activ
site
crystal
structur
spi
bound
saceangii
complex
lowest
score
dock
simul
chosen
run
fourth
md
simul
last
spi
bound
sace
model
gener
remov
angii
dock
simul
result
forc
field
explicit
water
molecul
use
simul
crystallograph
water
molecul
chlorid
ion
zinc
ion
retain
found
xray
crystal
structur
ligand
chemic
compon
origin
crystal
structur
includ
acet
ion
betadmannos
nacetyldglucosamin
also
retain
model
charmm
gener
forc
field
five
simul
system
solvat
truncat
octahedr
box
water
molecul
respect
solvat
system
electr
neutral
ad
counter
ion
final
salt
concentr
becam
simul
perform
namd
period
boundari
condit
solvat
step
energi
minim
perform
remov
possibl
bad
contact
md
simul
start
gradual
heat
system
k
ps
constant
volum
condit
order
equilibr
densiti
system
simul
switch
constant
pressur
temperatur
npt
condit
continu
afterward
averag
pressur
temperatur
maintain
bar
k
respect
heavi
atom
energi
minim
heat
first
ps
npt
simul
restrain
harmon
potenti
forc
constant
harmon
posit
restraint
remov
allow
atom
system
relax
bond
involv
hydrogen
atom
constrain
allow
integr
time
step
fs
nonbond
interact
smoothli
truncat
cutoff
particlemesh
ewald
method
use
treat
longrang
electrostat
interact
equilibr
stage
simul
determin
base
rmsd
system
energi
calcul
total
simul
equilibr
time
bppbsace
angiisac
apo
spisaceangii
spisac
respect
nanosecond
summari
md
simul
provid
tabl
product
stage
discard
initi
equilibr
stage
use
post
simul
analysi
except
rmsd
calcul
post
analys
visual
carri
visual
molecular
dynam
vmd
program
format
hydrogen
bond
identifi
use
donoracceptor
distanc
degre
protondonoracceptor
angl
criteria
